Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Senju
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca
Phase 2: Conduct Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DELTA-1 Study | P3 |
Completed |
Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2019-03-15 |
26% |
| SJP-0035/2-02 | P2 |
Completed |
Conduct Disorder |
2017-05-03 |
|
| SJP-0035/2-01 | P2 |
Completed |
Conduct Disorder |
2015-08-04 |
32% |